Napoli Bern Ripka & Associates, LLP Announces Lawsuits Continue to be Filed in the...

Napoli Bern Ripka & Associates, LLP Announces Lawsuits Continue to be Filed in
the Wake of Bayer Pulling Trasylol From the Market

NEW YORK, April 20, 2009 (GLOBE NEWSWIRE) -- In the wake of Bayer's announcement
that it had pulled its controversial heart surgery drug Trasylol from the market
in November 2007 after a Canadian study suggested that its use increased
surgical complications and death rates, nationally known plaintiffs' advocates
Napoli Bern Ripka & Associates, LLP by Marc Jay Bern, a Senior Partner at the
firm, who oversees the firm's Trasylol litigation, have filed another lawsuit
seeking damages on behalf of a heart surgery patient who after being
administered Trasylol (Aprotonin), experienced renal failure requiring ongoing
medical treatment.

The lawsuit, Gary A. Rowlett and Roxie A. Rowlett v. Bayer Corporation, et al.,
was filed in the United States District Court for the Southern District of
Florida. The patient, Gary A. Rowlett experienced renal failure after aortic
valve replacement where Trasylol (Aprotinin), a drug used to minimize
intraoperative bleeding, was administered. A case filed earlier by Napoli Bern
Ripka & Associates, Randone v. Bayer, was the subject of a profile on the CBS
newsmagazine "60 Minutes," on February 17, 2008, entitled "One Thousand Lives A
Month." Mr. Randone suffered kidney failure and other serious complications
caused by his physicians' use of Trasylol that ultimately resulted in his death.

The Ottawa Health Research Institute stopped their study of Trasylol in 3,000
heart bypass and valve surgery patients, upon their finding that while those
given the drug suffered less intraoperative bleeding, they had a 50% higher
chance of dying post surgically than those patients who were given one or
another of two older medical alternatives. Dr. John K. Jenkins, an official of
the Food and Drug Administration, said the "F.D.A. could not identify a specific
patient population where the benefits of using Trasylol could outweigh the
risks." The F.D.A. said that the fact that the Ottawa group ended their study
early was a strong factor in their decision to request that Bayer withdraw the
drug from the market.

About the Firm:

Napoli Bern Ripka & Associates, LLP, a nationally-known law firm advocating on
behalf of injured plaintiffs in pharmaceutical and environmental tort matters,
is based in Manhattan and Great River, New York, and has offices in
Philadelphia, New Jersey, and Oklahoma. The firm has successfully litigated
claims of thousands of persons injured by the diet drugs Fenfluramine and
dexfenfluramine (Reduxtm), Rezulin, Propulsid and represents clients in
environmental claims arising from petroleum spills and MTBE contamination
throughout the eastern United States, as well as over ten thousand plaintiffs
suffering toxic exposure injuries after working on the debris pile at the site
of the World Trade Center following the September 11, 2001 attacks.

-0-
CONTACT: Napoli Bern Ripka & Associates, LLP
Marc Jay Bern, Esq.
(212) 267-3700
mjbern@napolibern.com
3500 Sunrise Hwy., Suite T-207
Great River, New York 11739